Cargando…

Molecular Mechanisms and Therapeutic Strategies for Levodopa-Induced Dyskinesia in Parkinson’s Disease: A Perspective Through Preclinical and Clinical Evidence

Parkinson’s disease (PD) is the second leading neurodegenerative disease that is characterized by severe locomotor abnormalities. Levodopa (L-DOPA) treatment has been considered a mainstay for the management of PD; however, its prolonged treatment is often associated with abnormal involuntary moveme...

Descripción completa

Detalles Bibliográficos
Autores principales: Bandopadhyay, Ritam, Mishra, Nainshi, Rana, Ruhi, Kaur, Gagandeep, Ghoneim, Mohammed M., Alshehri, Sultan, Mustafa, Gulam, Ahmad, Javed, Alhakamy, Nabil. A., Mishra, Awanish
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Frontiers Media S.A. 2022
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9021725/
https://www.ncbi.nlm.nih.gov/pubmed/35462934
http://dx.doi.org/10.3389/fphar.2022.805388
_version_ 1784689896656470016
author Bandopadhyay, Ritam
Mishra, Nainshi
Rana, Ruhi
Kaur, Gagandeep
Ghoneim, Mohammed M.
Alshehri, Sultan
Mustafa, Gulam
Ahmad, Javed
Alhakamy, Nabil. A.
Mishra, Awanish
author_facet Bandopadhyay, Ritam
Mishra, Nainshi
Rana, Ruhi
Kaur, Gagandeep
Ghoneim, Mohammed M.
Alshehri, Sultan
Mustafa, Gulam
Ahmad, Javed
Alhakamy, Nabil. A.
Mishra, Awanish
author_sort Bandopadhyay, Ritam
collection PubMed
description Parkinson’s disease (PD) is the second leading neurodegenerative disease that is characterized by severe locomotor abnormalities. Levodopa (L-DOPA) treatment has been considered a mainstay for the management of PD; however, its prolonged treatment is often associated with abnormal involuntary movements and results in L-DOPA-induced dyskinesia (LID). Although LID is encountered after chronic administration of L-DOPA, the appearance of dyskinesia after weeks or months of the L-DOPA treatment has complicated our understanding of its pathogenesis. Pathophysiology of LID is mainly associated with alteration of direct and indirect pathways of the cortico-basal ganglia-thalamic loop, which regulates normal fine motor movements. Hypersensitivity of dopamine receptors has been involved in the development of LID; moreover, these symptoms are worsened by concurrent non-dopaminergic innervations including glutamatergic, serotonergic, and peptidergic neurotransmission. The present study is focused on discussing the recent updates in molecular mechanisms and therapeutic approaches for the effective management of LID in PD patients.
format Online
Article
Text
id pubmed-9021725
institution National Center for Biotechnology Information
language English
publishDate 2022
publisher Frontiers Media S.A.
record_format MEDLINE/PubMed
spelling pubmed-90217252022-04-22 Molecular Mechanisms and Therapeutic Strategies for Levodopa-Induced Dyskinesia in Parkinson’s Disease: A Perspective Through Preclinical and Clinical Evidence Bandopadhyay, Ritam Mishra, Nainshi Rana, Ruhi Kaur, Gagandeep Ghoneim, Mohammed M. Alshehri, Sultan Mustafa, Gulam Ahmad, Javed Alhakamy, Nabil. A. Mishra, Awanish Front Pharmacol Pharmacology Parkinson’s disease (PD) is the second leading neurodegenerative disease that is characterized by severe locomotor abnormalities. Levodopa (L-DOPA) treatment has been considered a mainstay for the management of PD; however, its prolonged treatment is often associated with abnormal involuntary movements and results in L-DOPA-induced dyskinesia (LID). Although LID is encountered after chronic administration of L-DOPA, the appearance of dyskinesia after weeks or months of the L-DOPA treatment has complicated our understanding of its pathogenesis. Pathophysiology of LID is mainly associated with alteration of direct and indirect pathways of the cortico-basal ganglia-thalamic loop, which regulates normal fine motor movements. Hypersensitivity of dopamine receptors has been involved in the development of LID; moreover, these symptoms are worsened by concurrent non-dopaminergic innervations including glutamatergic, serotonergic, and peptidergic neurotransmission. The present study is focused on discussing the recent updates in molecular mechanisms and therapeutic approaches for the effective management of LID in PD patients. Frontiers Media S.A. 2022-04-07 /pmc/articles/PMC9021725/ /pubmed/35462934 http://dx.doi.org/10.3389/fphar.2022.805388 Text en Copyright © 2022 Bandopadhyay, Mishra, Rana, Kaur, Ghoneim, Alshehri, Mustafa, Ahmad, Alhakamy and Mishra. https://creativecommons.org/licenses/by/4.0/This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) and the copyright owner(s) are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.
spellingShingle Pharmacology
Bandopadhyay, Ritam
Mishra, Nainshi
Rana, Ruhi
Kaur, Gagandeep
Ghoneim, Mohammed M.
Alshehri, Sultan
Mustafa, Gulam
Ahmad, Javed
Alhakamy, Nabil. A.
Mishra, Awanish
Molecular Mechanisms and Therapeutic Strategies for Levodopa-Induced Dyskinesia in Parkinson’s Disease: A Perspective Through Preclinical and Clinical Evidence
title Molecular Mechanisms and Therapeutic Strategies for Levodopa-Induced Dyskinesia in Parkinson’s Disease: A Perspective Through Preclinical and Clinical Evidence
title_full Molecular Mechanisms and Therapeutic Strategies for Levodopa-Induced Dyskinesia in Parkinson’s Disease: A Perspective Through Preclinical and Clinical Evidence
title_fullStr Molecular Mechanisms and Therapeutic Strategies for Levodopa-Induced Dyskinesia in Parkinson’s Disease: A Perspective Through Preclinical and Clinical Evidence
title_full_unstemmed Molecular Mechanisms and Therapeutic Strategies for Levodopa-Induced Dyskinesia in Parkinson’s Disease: A Perspective Through Preclinical and Clinical Evidence
title_short Molecular Mechanisms and Therapeutic Strategies for Levodopa-Induced Dyskinesia in Parkinson’s Disease: A Perspective Through Preclinical and Clinical Evidence
title_sort molecular mechanisms and therapeutic strategies for levodopa-induced dyskinesia in parkinson’s disease: a perspective through preclinical and clinical evidence
topic Pharmacology
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9021725/
https://www.ncbi.nlm.nih.gov/pubmed/35462934
http://dx.doi.org/10.3389/fphar.2022.805388
work_keys_str_mv AT bandopadhyayritam molecularmechanismsandtherapeuticstrategiesforlevodopainduceddyskinesiainparkinsonsdiseaseaperspectivethroughpreclinicalandclinicalevidence
AT mishranainshi molecularmechanismsandtherapeuticstrategiesforlevodopainduceddyskinesiainparkinsonsdiseaseaperspectivethroughpreclinicalandclinicalevidence
AT ranaruhi molecularmechanismsandtherapeuticstrategiesforlevodopainduceddyskinesiainparkinsonsdiseaseaperspectivethroughpreclinicalandclinicalevidence
AT kaurgagandeep molecularmechanismsandtherapeuticstrategiesforlevodopainduceddyskinesiainparkinsonsdiseaseaperspectivethroughpreclinicalandclinicalevidence
AT ghoneimmohammedm molecularmechanismsandtherapeuticstrategiesforlevodopainduceddyskinesiainparkinsonsdiseaseaperspectivethroughpreclinicalandclinicalevidence
AT alshehrisultan molecularmechanismsandtherapeuticstrategiesforlevodopainduceddyskinesiainparkinsonsdiseaseaperspectivethroughpreclinicalandclinicalevidence
AT mustafagulam molecularmechanismsandtherapeuticstrategiesforlevodopainduceddyskinesiainparkinsonsdiseaseaperspectivethroughpreclinicalandclinicalevidence
AT ahmadjaved molecularmechanismsandtherapeuticstrategiesforlevodopainduceddyskinesiainparkinsonsdiseaseaperspectivethroughpreclinicalandclinicalevidence
AT alhakamynabila molecularmechanismsandtherapeuticstrategiesforlevodopainduceddyskinesiainparkinsonsdiseaseaperspectivethroughpreclinicalandclinicalevidence
AT mishraawanish molecularmechanismsandtherapeuticstrategiesforlevodopainduceddyskinesiainparkinsonsdiseaseaperspectivethroughpreclinicalandclinicalevidence